and osteocalcin in MC3T3-E 1 osteoblast like cells, and enhanced the formation of mineralized bone nodules from bone marrow mesenchymal stem cells. We suggest that BMP1-3 is a novel systemic regulator of bone repair.
In purified plasma samples from healthy volunteers using liquid chromatography-mass spectrometry (LC-MS), we identified BMP1-3 isoform of the Bmp1 gene [1] . BMP1 (procollagen C proteinase-1; BMP1) and mammalian tolloid (mTLD/BMP1-3) are alternatively spliced products of the Bmp1 gene. BMP1 was originally isolated from bone with other BMPs due to its affinity for heparin; however, it is not an authentic member of the BMP protein family and belongs to the astacin/BMP1/tolloid (TLD)-like family of zinc metalloproteinases which are fundamental in the development and formation of the extracellular matrix (ECM) [2] [3] [4] [5] . The BMP1-like proteases share a common domain structure that includes an amino-terminal prodomain that is cleaved to yield the mature protease. Mature BMP1 consists of the metalloprotease domain followed by EGF-like motifs and three complement domains (CUB), thought to be involved in protein-protein interaction. Mature BMP1-3 has two more CUB domains (CUB IV and CUB V).The C-terminal domains have been shown to control and restrict the BMP1 substrate specificity, so difference between BMP1 and BMP1-3 in number of CUB domains maybe important for differences in the activity and specificity of these molecules particularly connected with organ and tissue targeting. BMP1-1 isoform is involved in the biosynthetic processing of a range of ECM precursors, including major and minor fibrillar collagens, the collagen and elastin cross-linking enzyme prolysyl oxidase [6] , cellular anchoring proteins prolaminin-5 [7] , and procollagen VII, and the small leucine-rich proteoglycans osteoglycin and probiglycan [8] . BMP1-1 also releases several TGFβ superfamily members, including BMP2 and BMP4, growth and differentiation factors (GDF) 8/11, and TGFβ1 from their corresponding latent complexes [5, [9] [10] [11] .
These dual roles have fuelled speculation that BMP1/TLD proteinases orchestrate the ECM assembly by means of signaling by TGFβ-like proteins.
The structural components of bone consist of extracellular matrix, collagen and cells. The noncollagenous protein and enzymes present in the bone matrix might influence its matrix and regulate bone formation.
Circulating BMP1-3 seems to be well suited as a biological control point for the regulation of collagen deposition 3 into the callus formation and bone regeneration. In this paper we therefore explored whether circulating BMP1-3 influences osteoblast function and bone fracture repair.
MATERIALS AND METHODS
Antibodies-Polyclonal antibodies against mature BMP1-3 and BMP1-1 were generated in rabbits immunized with specific synthetic peptides: BMP1-3 (aa759-772; CTSPNWPDKYPSKKE) and BMP1-1 (aa705-717. Peptide specific antibodies were affinity purified (Multiple Peptide Systems), and their crossreactivity and neutralizing effect were tested (data not shown).
Cloning and expression of BMP1 isoforms-Human BMP1-3 cDNA was synthesized from the human adult normal placenta total RNA using the SuperScript TM III First-Strand Synthesis System (Invitrogen). To generate the pcDNA TM 3.2/V5-DEST expression clone, the sequence confirmed by pENTR221/BMP1-3 was recombined with the pcDNA TM 3.2/V5-DEST vector in an LR recombination reaction (Invitrogen Gareway® Technology). The mammalian expression plasmid pSecTag2 Bmp1-3 was transfected into FreeStyle™ CHO cells using the FreeStyle™ MAX transfection reagent. The protein was affinity-purified via a BMP1-3 specific antibody column.
Gene expression analysis-Total RNA was isolated from MC3T3 cells using TRIzol (Invitrogen). cDNA was synthesized and amplified from 1 µg of total RNA using Super Script III First-Strand Synthesis System (Invitrogen). Gene expression of interest was measured by using a LightCycler FastStart DNA Master SYBR Green kit in a LightCycler instrument (Roche Diagnostics), as described [12] . Gapdh was used as normalized gene.
Results are represented as a fold change of the comparative expression level. The list of primers used is shown in Table 1 .
Human tissue, immunohistochemistry and morphometric analysis-Human embryos and fetuses ranging from 5-14 weeks of gestation [10-52 mm crown-rump length (CRL)] used in the present study were collected at the University of Zagreb Medical School as previously described [13] [14] [15] and controlled by the Internal Review
Board of the Ethics Committee at the University of Zagreb Medical School [16] . Immunocytochemistry was 4 performed using the immunoperoxidase detection system (Zymed) and photographs were taken by Olympus Provis microscope.
Rat femoral fracture model-An osteotomy in the proximal third of the femur was made in male SpragueDawley rats (250-300 g) using a circular saw. The fragments were repositioned under general anesthesia and fixed by an intramedullary Kirschner pin. The rats were randomly assigned to one of the groups (n=8): A/ control, only osteotomy; B/ control with non-immune rat IgG; C/ osteotomy receiving rhBMP1-3 iv, 3x/week (3 µg); D/ osteotomy receiving BMP1-3 antibody iv, 1x/week (50 µg). The effect of the treatment was monitored by radiographs every two weeks up to the 6th week when the animals were killed.
Critical size defect of rabbit ulna-An ulnar critical size defect model was used to evaluate the efficacy of BMP1-3 in bone healing of adult male New Zealand White rabbits (3 to 4 kg weight), as previously described [17] . Shortly, blood was collected from rabbit marginal ear veins into tubes without any anticoagulant substance.
BMP1-3 (20 µg) with or without BMP7 (100 µg) was added into the blood supplemented with 10 mM CaCl 2 .The coagulum whole blood containing device (WBCD) was modified to provide a rigid and flexible carrier and used for the treatment [18, 19] . Animals were divided into four groups ( MicroCT-The microcomputerized tomography machine and the analyzing software were obtained from SkyScan [20, 21] . Rabbit ulna analysis started just above the site of the critical size defect and continued in the dorsoventral direction embracing the entire ulnar defect and the healthy radius. However, only new trabecular bone in the ulnar defect was depicted and analyzed in three dimensions. Rat femur analysis started by determining the connection of proximal growth plates as a reference point from which 100 slices distally were set as offset and 200 slices were analyzed for trabecular bone and new bone formation [21] .
Bone nodule formation assay-Bone marrow cells were harvested from femurs and tibias of four 8-week-old WT mice, pooled and plated at 7 x 10 6 /well on 6 well plates in αMEM, containing 10% fetal calf serum (FCS).
Half the volume of the medium was changed on day 3. Differentiation medium containing αMEM, 10% FCS, 8 mM β-glycerophosphate, 50 µg/ml ascorbic acid and 10 -8 M dexamethasone was added on day 7. The medium was subsequently changed every two days until the culture was terminated. BMP1-3 (150 ng/ml) and BMP1-3 antibody (1 µg/ml) were added to the medium at every feeding. At day 21 of cell culture, the von Kossa stain was used to determine the mineralized matrix formation. Quantification of the mineralized area was performed using SForm software and expressed as percentage of the mineralized area.
MC3T3-E1 cells -The mouse osteoblast-like MC3T3-E1 cell line, derived from newborn mouse calvaria as described [22] . Cultured cells were divided into two groups: control and cells treated every second day with BMP1-3 (50 ng/ml). After treating the cells 3 times, total RNA was extracted with TRIzol (Gibco BRL, Grand
Island, NY, USA). Cells were plated at 2,5x10 4 cells / well in 48-well plates. After 24 hours the medium was changed to serum-free medium for 7 hours [23] . Cells were then treated for 17 hours in DMEM/F-12 with BMP7 [24] , washed with chilled PBS (Invitrogen) and lysed in reporter lysis buffer (Promega). Luciferase activity was measured using the Promega luciferase assay reagent on Victor Wallack luminometer. BMP1-3, BMP7 and a control peptide with mixed amino acids from BMP heparin binding site sequence (piChem) were used in the assay.
Id-1 reporter assay for measuring BMP activity-
Statistics-All data are presented as mean ± SD. One way analysis of variance (ANOVA) was performed to determine the effect of BMP1-3 and BMP1-3 antibody treatment efficacy on the bone and kidney. Statistical evaluation of the survival rate was carried out by the Petö-Wilcoxon test. The results were considered significant when P was < 0.05.
RESULTS
Circulating BMP1-3 supports fracture repair in rats-To examine whether the circulating BMP1-3 is physiologically relevant for bone modeling in rats we chose a model of fracture repair. Administration of a 6 neutralizing polyclonal BMP1-3 antibody, intravenously (iv) to rats with a fractured femur resulted in significantly delayed bone union (Fig. 1D) . In contrast, systemic administration of the BMP1-3 protein for a period of 6 weeks (3 µg/3x week) increased the bone volume and accelerated the fracture repair (Fig.1C) . Ex vivo microCT analyses of femurs showed that the bone volume (BV) of rats treated with rhBMP1-3 (3 µg, 3x/week) was 20% increased and was 55% higher as compared to rats treated with the BMP1-3 antibody (50 µg, 1x/week) (Fig.1) .
Expression of BMP1-3 in human bone development-To assess the potential colocalization of BMP1-3
with other bone morphogenetic proteins we investigated its expression during the human development. Up to 8
weeks of gestation both BMP1-3 and BMP1-1 were localized in the epithelial ectoderm of the growing limb ( Fig.2 A-C) . Following the hypertrophy of chondrocytes, prior to vascular invasion, they were expressed in the periosteal bone collar, in the surrounding ECM and in the cells of osteoblastic lineage (Fig. 2D-H ). Fetuses at 10-14 weeks of gestation showed BMP1-3 restricted to the epithelial ectoderm (Fig.2B) , where it co-localized with BMP7 (data not shown). BMP1-3 isoforms were not localized in the areas of intramembranous bone formation (Fig. 2B) .
Locally administered BMP1-3 accelerates and enhances bone regeneration-Based on the localization of
BMP1-3 in the human development where it co-localizes with BMP7, we next tested their individual and combined local efficacy in rabbits with a critical size bone defect of the ulna. BMP1-3 ( Fig. 3B) individually stimulated bone formation. The combination of BMP1-3 with BMP7 had an additive effect on bone repair, which at 6 weeks resulted in the rebridgement of the cortical bone and advanced remodeling of the trabecular bone (Fig.   3D ). In contrast, 6 weeks following surgery, individual therapy with BMP1-3 or BMP7 (Fig. 3B, C) did not result in the rebridgement of the ulnar defect with newly formed and mineralized bone. MicroCT analysis of the critical size defect area showed a 28% increased BV/TV in rabbits treated with the combination of BMP1-3 and BMP7 (Fig.3D) . Histomorphometry of Goldner stained histology sections confirmed the µCT results, showing a high percentage of newly formed bone (38%) with a well established medullary canal in the same group (Fig. 3E) .
However, at 6 weeks following therapy, bone defects treated with BMP1-3 alone stimulated in particular the trabecular bone formation, without a clearly formed cortical bridge and without remodeling of the trabecular bone (Fig. 3B, histology panel) . Similarly, BMP7 treated bone defects were filled with newly formed trabecular bone without signs of advanced remodeling and cortical rebridgement (Fig. 3C, histology panel) .
BMP1-3 affects osteoblast differentiation in vitro-
The exogenous BMP1-3 enhanced the differentiation of bone marrow-derived MSC towards osteoblasts as evidenced by increased mineralized bone nodule formation as compared to control cultures after staining with van Kossa (Fig. 4 B, D) . Treatment of MSC with the BMP1-3
antibody had an opposite effect on mineralized bone nodule formation (Fig. 4 C, D) . Gene expression analysis of MC3T3E1 pre-osteoblasts treated with BMP1-3 protein indicated an increased expression of procollagen, BMP1-3 and osteocalcin, and decreased expression of Bmp6 and Bmp7 (Fig.4 E) , suggesting that the enhanced maturation of MSC into osteoblasts was not mediated via BMPs, while increased BMP1-3 expression level might have supported the accelerated fracture healing in rats and rabbits via processing of ECM (Fig.1, 3 ). BMP1-3
antibody added to MC3T3E1 cell cultures increased the expression of Bmp6 and Bmp7 (date not shown)
BMP1-3 enhances activity of BMP7 in vitro-When added to C2C12 cells stably transfected with the BMP
response element (BRE) from the Id-1 gene promoter fused to a luciferase reporter gene, BMP1-3 had no effect on luciferase induction. However, in combination with BMP7 it significantly enhanced the BMP7 activity (Fig.4 F). We suggest that BMP1-3 acts as a coactivator of BMP7, but the exact mechanism has to be established.
DISCUSSION
The role of BMP-1 in promoting bone regeneration has not been previously evidenced. In the original discovery by Wozney at al. [25] it was suggested that recombinant human BMP-1 implanted with a bovine collagen in a rat subcutaneous assay induced new bone formation. However, this was an artifact of the rat growth plate chondrocytes isolated together with the demineralized bone matrix preparation [26] . Since the bone fracture healing process is thought to recapitulate skeletal development, and since BMP1-3 is highly expressed in the limb development we hypothesized that BMP1-3 plays an important role in fracture healing. Utilizing a rat femur fracture model and the osteoblast differentiation culture, the present studies demonstrates that the inhibition of BMP1-3 leads to a significant delay in the fracture healing process, and that BMP1-3 plays a role in the osteoblast 8 differentiation and bone formation. Following the localization of BMP1 in human development we assumed that BMP1-3 in circulation might systemically influence the acceleration of ECM deposition.
For the proper bone formation functional relationships between proteinases and growth factor and bone cells must be achieved, because they are all necessary for normal ossification and bone ECM remodeling [27] . For cells to migrate through matrix during the healing process, the matrix degradation surrounding the migrating cells is required. The initial step of angiogenesis includes the migration of endothelial cells and also involves proteolytic degradation of ECM.
BMP1-3 enhanced the bone formation when implanted locally in combination with BMP7. The combination potentially associates two independent, but synergistic functions essential to the healing process, stimulation of cells proliferation and differentiation by BMP7, and facilitating cell migration by clearing the extracellular matrix components by BMP1-3. This combination may be used for supporting bone healing and the regeneration process [28] . In addition, BMP1-3 enhanced the Id gene expression activity of BMP7 in C 2 C 12 myoblasts in vitro, which might in vivo contribute to successful bone repair. BMP1-3 eventually contributes to the bone regeneration via stimulating the synthesis and processing of ECM proteins and via increased formation of osteoblasts from MSC. BMP1-3 also increased bone nodule formation and osteoblast differentiation. It is well known that proteinases (MMPs) safeguard osteoblasts from apoptosis and maintain osteocyte viability. During bone development, ECM remodeling is required for osteoblast differentiation and the process is largely mediated by the proteolitic activity of MMPs which play a fundamental role in osteoblast migration. Expression of a collagen type I in the murine calvarial osteoblast cell line MC3T3-E1 after treatment with BMP1-3 may result in deposition of a type I collagen matrix which is specific for a period of rapid cell division. Exposure to BMP1-3 increases the collagen type I and osteocalcin expression. Osteoblast, nuclear matrix, DNA-binding proteins, with a capacity for bending DNA, recognize elements on the osteocalcin and type I collagen promoters. This establishes a physical link between the regulation regions of osteoblast ECM genes and cell structure [29] The stimulation of osteocalcin gene expression in the presence of a rapid matrix turnover suggests a more complex mechanism for its regulation. Osteocalcin may be regulated by factors released from osteoblast matrix undergoing high rates of 9 turnover. Collagen type I may act directly on cellular receptors or it might be merely required as a latticework for other matrix proteins which themselves interact directly with cells. The precise mechanism of BMP1-3 action must be therefore further explored.
Systemic administration of the specific BMP1-3 antibody delayed the bone healing confirming that the amount of circulating BMP1-3 is relevant for bone repair. This was accompanied with a more than 50% decreased circulating level of TGF-β1 [1] , which might have contributed as well to the delayed bone formation due to its known stimulatory effect on osteoblast proliferation. Also delayed fracture healing or nonunion formation may be associated with alternations in the MMP system. Measurement of BMP1-3 in plasma in patients with fracture might be a precious performance indicator for the bone healing process.
In conclusion, this study provides in vivo and in vitro evidence for the critical role of BMP1-3 in bone fracture repair. 
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